Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial
Karim Fizazi(Institut Gustave Roussy), Mika Mustonen(Orion Corporation (United Kingdom)), Peter Langmuir(Endo Pharmaceuticals (United States)), Teuvo L.J. Tammela(Tampere University), Nicholas D. James(University of Warwick), Annamari Vuorela(Orion Corporation (United Kingdom)), Vesa Kataja(South Eastern Finland University of Applied Sciences), Robert H. Jones(Clinical Research Institute), Andrew Protheroe(Churchill Hospital), Tony Elliott(The Christie Hospital), Leena Mattila(University of Turku), Christophe Massard(Institut Gustave Roussy), John Aspegrén(Orion Corporation (Finland)), Jorge A. García(Cleveland Clinic), Petri Bono(Helsinki University Hospital)
Cited by 194
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k